Join
Live feed
·
PRReleasevia Quantisnow
Longboard Pharmaceuticals Inc. logo

Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)

ByQuantisnow·Wall Street's wire, on your screen.
LBPH· Longboard Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LBPH (Longboard Pharmaceuticals Inc.) and more on Quantisnow.